MONDAY, FEBRUARY 21
Welcome and Keynote Address
Thomas C. Südhof, Stanford School of Medicine, USA
Neurotransmitter Release and Neurodegeneration: The SNARE Connection

TUESDAY, FEBRUARY 22
Cognitive and Emotional Deficits in Neurodegenerative Disorders: From Molecules to Phenotypes
*Holly Soares, Bristol-Myers Squibb, USA
Akira Sawa, Johns Hopkins University, USA
Molecular Link of Huntingtin-PDE4-DISC1: Potential Impact on Emotional and Cognitive Deficits in Huntington’s Disease
Dezhi Liao, University of Minnesota, USA
Tau Mislocalization in Neurodegenerative Diseases
Tracy L. Young-Pearse, Brigham and Women’s Hospital and Harvard Medical School, USA
Bidirectional Signal Crosstalk between APP and DISC1 in Neurodevelopment and Aging
Li-Huei Tsai, Massachusetts Institute of Technology, USA
Epigenetics in Cognitive Performance and Alzheimer’s Disease
Sreeganga S. Chandra, Yale University, USA
Short Talk: alphabeta-gamma-Synuclein Triple Knockout Mice Reveal Age-Dependent Neuronal Dysfunction
Amantha Thathiah, Catholic University of Leuven, Belgium
Short Talk: GPR3 Modulation the gamma-secretase Complex and Ataxin-3 Promotes Clearance of Parkin Through the Autophagy Pathway

Monitoring Neurodegenerative Disease Progression
*Lennart Mucke, University of California, San Francisco, USA
David M. Holtzman, University of Pennsylvania, USA
CSF Biomarkers: Correlations with Imaging and Value in Diagnosis and Prognosis
John Q. Trojanowski, University of Pennsylvania, USA
Progress in Alzheimer’s Disease (AD) Biomarkers from the AD Neuroimaging Initiative (ADNI)
Holly Soares, Bristol-Myers Squibb, USA
Utility of Multiplied Panels as Screening Tools for Early Detection of Neurodegeneration
Philipp Jaeger, Stanford University, USA
Short Talk: Comparative Plasma Proteomics between FTLD Patients with Semantic Dementia and Progranulin Mutation Carriers Reveals a Novel Immunological Component for the Disease
Joel C. Watts, University of California San Francisco, USA
Short Talk: Bioluminescence Imaging of Abeta Deposition in Transgenic Mouse Models of Alzheimer’s Disease

WEDNESDAY, FEBRUARY 23
Anatomical and Functional Basis of Dementia and Neurodegeneration
*Li-Huei Tsai, Massachusetts Institute of Technology, USA
Lennart Mucke, University of California, San Francisco, USA
Key Roles of Tyrosine Kinases and Tau in Abeta-Induced Neuronal Dysfunction
Brian J. Bacsuk, Massachusetts General Hospital, USA
Imaging Structural and Functional Alterations in AD Models
Lynn A. Raymond, University of British Columbia, Canada
The Role of Excitotoxicity in Neurodegeneration in Huntington Disease
James Surmeier, Northwestern University, USA
Phenotypic Determinants of Neuronal Vulnerability in Parkinson’s Disease
Joshua M. Shulman, Brigham & Women’s Hospital, USA
Short Talk: Enhancing Power for Gene Discovery in Alzheimer’s Disease: Intermediate Phenotypes and Functional Validation in Drosophila
Todd J. Cohen, University of Pennsylvania, USA
Short Talk: Tau Acetylation Inhibits Function and Promotes Tau Pathology in Alzheimer’s Disease

Mitochondria and Protein Quality Control Dysfunction in Neurodegeneration
*Ted M. Dawson, Johns Hopkins School of Medicine, USA
Ming Guo, University of California, Los Angeles, USA
Mitochondrial Fission and Fusion in Parkinson’s Disease
Richard J. Youle, NINDS, National Institutes of Health, USA
Damage Control - How the Pink1/Parkin Pathway can Regulate Removal of Impaired Mitochondria by Autophagy
Ana María Cuervo, Albert Einstein College of Medicine, USA
Selective Autophagy in Neurodegeneration
Jin-Mi Heo, University of Utah, USA
Short Talk: Identification of Vms1 as a Novel Mitochondrial Stress Responsive Protein Involved in Mitochondrial Protein Quality Control
Thomas M. Durcan, Montreal Neurological Institute, Canada
Short Talk: The Machado-Joseph Disease Associated Mutant Form of Ataxin-3 Promotes Clearance of Parkin Through the Autophagy Pathway

THURSDAY, FEBRUARY 24
Neurodegeneration Due to RNA and DNA Regulatory Proteins
*Stephen M. Strittmatter, Yale University, USA
Virginia M.-Y. Lee, University of Pennsylvania School of Medicine, USA
TDP-43 Proteinopathies
Don W. Cleveland, University of California, San Diego, USA
Rethinking ALS: What’s All the FUS?
**Neurodegenerative Diseases: The Molecular and Cellular Basis for Neurodegeneration (F2)**

February 21-26, 2011 • Sagebrush Inn and Conference Center • Taos, New Mexico • USA


Sponsored by AstraZeneca Pharmaceuticals, L.P., Genentech, Inc. and Isis Pharmaceuticals, Inc.

Program current as of February 14, 2011. Program subject to change. For the most up-to-date details, visit www.keystonesymposia.org/11F2.

* Session Chair † Invited but not yet accepted

---

**Aaron D. Gitler**, University of Pennsylvania, USA
*Novel RNA Binding Proteins in ALS*

**Ted M. Dawson**, Johns Hopkins School of Medicine, USA
*Parkin, Paris and PGC-1alpha: A Novel Neurodegenerative Pathway in Parkinson's Disease*

**Miriam E. Bucheli**, Harvard University, Harvard Medical School, USA
*Short Talk: A Combinatorial Approach to Identify Common Regulatory Targets for FUS/TLS, TDP-43 and SETX*

**Thomas Kukar**, Emory University, USA
*Short Talk: Somatic Brain Transgenic FUS Mice*

**John Q. Trojanowski**, University of Pennsylvania School of Medicine, USA
*Beyond Abeta Based Therapies: Developing Novel Modulators of Synaptic Transmission*

**Per I. Arvidsson**, AstraZeneca R&D, Sweden
*Inhibitors of LRRK2 Kinase: Mechanism-Based Therapy for Parkinson's Disease*

**Anatoly Nikolaev**, Genentech, USA
*Short Talk: APP-Death Receptor Signaling Pathway as a Drug Target in Neurodegenerative Disease*

**Giovanna R. Mallucci**, University of Leicester, UK
*Short Talk: Acute Depletion of PrP May Abrogate Abeta Oligomer Toxicity*

**Harald Neumann**, University Bonn, Germany
*Short Talk: Human Induced Pluripotent Stem Cell-Derived Microglia (iPSdM) as Tool to Study Neurodegenerative Diseases*

**Lindsay Hayes**, Brown University, National Institutes of Health, USA
*Short Talk: The Timing of Sonic Hedgehog and Gli1 Expression Segregates Midbrain Dopamine Neurons*

---

**FRIDAY, FEBRUARY 25**

**Prion and Prion-Like Contributions to Neurodegeneration**

**†Virginia M.-Y. Lee**, University of Pennsylvania School of Medicine, USA
*Prion-Like Seeding of Cerebral Abeta Deposition in Transgenic Models of Alzheimer-Type Proteopathy*

**†Lary C. Walker**, Emory University, USA
*Prion-Like Protease Propagation in Synucleinopathies: Prospects for Therapeutical Interventions*

**Markus Tolnay**, Basel University Hospital, Switzerland
*Transmission and Spreading of Tauopathy in Transgenic Mouse Brain*

**†Eliezer Masliah**, University of California, San Diego, USA
*Prion-Like Protein Propagation in Synucleinopathies: Prospects for Therapeutical Interventions*

**Stephen M. Strittmatter**, Yale University, USA
*Prion-like Oligomer Binding to Post-Synaptic Prion Protein Activates Fyn to Alter NMDA Receptors, Dendritic Spines and Epileptiform Activity*